ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Chicago Sky Blue 6B modulates MAPK/NF-kB pathway in rat knee osteoarthritis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Knee osteoarthritis (OA) has emerged as a growing public health concern in recent years. We aimed to investigate the impact of Chicago Sky Blue 6B (CSB) on OA progression in rats. In this study, we established a rat OA model using DMM surgery and conducted histological staining to assess the overall morphology of rat knee joints, as well as the content of proteoglycans and collagen upon CSB treatment. Additionally, in vitro experiments were performed using qPCR and WB to detect the expression of matrix molecules and matrix-degrading enzymes. The expression of relevant proteins in the MAPK/NF-kB pathway was also examined. Our in vitro experiments show that IL-1β decreased Aggrecan and COL2A1 gene expression and increased MMP3, MMP13 and ADAMTS5 gene expression. CSB treatment alleviated the IL-1β-induced inflammatory response. Further experiments indicated that CSB inhibited downstream inflammatory responses by suppressing the MAPK/NF-kB pathway. In vivo experiments confirmed the therapeutic effect of CSB in alleviating OA induced by DMM surgery in rats. We demonstrated that CSB could alleviate OA in rats through the MAPK/NF-kB pathway, highlighting its potential as a therapeutic agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.